Immunexpress to Present SeptiCyte® RAPID Comparative Data Against Lactate and Procalcitonin for Diagnosing Sepsis at IDWeek 2021

Immunexpress.com

Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced a presentation demonstrating comparative data of SeptiCyte® RAPID, lactate, and procalcitonin in differentiating sepsis from infection negative systemic inflammation at IDWeek 2021, taking place virtually on Sept. 29 – Oct. 3, 2021.   Details of the presentations are as…

Read More

Immunexpress Announces SeptiCyte® RAPID Testing For Paediatric Sepsis

Immunexpress.com

BRISBANE, Australia, Aug. 24, 2021 /PRNewswire/ — Immunexpress, Pty Ltd, a molecular diagnostic company founded in Brisbane, today announced that the SeptiCyte® RAPID test will be evaluated in the diagnosis of paediatric sepsis in Queensland children. The testing is in part funded through a Federal Government’s Medical Research Future Fund Genomic Health Futures Mission grant for collaborative work between The University of…

Read More

Immunexpress Presents Data Supporting SeptiCyte® RAPID for COVID-19 Patient Triage as a Late-Breaking Abstract at ECCMID 2021

Immunexpress.com

SEATTLE, July 9, 2021 – Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced a late-breaking presentation, titled “Use of SeptiCyte RAPID to assess the risk of ICU admission in COVID-19 patients” (ID#4984), demonstrating the performance of SeptiCyte® RAPID in triaging COVID-19 patients at the 31st European Congress…

Read More

Immunexpress Presents Data Further Demonstrating SeptiCyte® RAPID Performance at the Society of Critical Care Medicine’s 50th Annual Critical Care Congress

Immunexpress.com

Data Demonstrate the Performance of SeptiCyte® RAPID is Unaltered by Patient Malignancy or Treatment with Anti-neoplastics or Immunosuppressants Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced a research snapshot presentation of clinical data demonstrating the performance of SeptiCyte® RAPID in adult and pediatric patients with sepsis or systemic…

Read More

Immunexpress to Present SeptiCyte® RAPID Performance Data at the 50th Critical Care Congress

Immunexpress.com

Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced the publication of an abstract for a research snapshot presentation to be presented as part of the Society of Critical Care Medicine’s (SCCM) 50th Annual Critical Care Congress being held virtually Jan. 31 through Feb. 12, 2021. The presentation highlights…

Read More

Immunexpress to Present SeptiCyte® RAPID Data at the Association for Molecular Pathology Annual Meeting

Immunexpress.com

Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced further SeptiCyte® RAPID data demonstrating performance, reproducibility and identification of fungal infections, in two poster presentations at the Association for Molecular Pathology (AMP) 2020 Annual Meeting & Expo on Nov. 16-20.   “Our SeptiCyte® technology leverages host-response gene-expression biomarkers…

Read More

Immunexpress to Present SeptiCyte® RAPID Data at the Association for Molecular Pathology Annual Meeting

Immunexpress.com

Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced that it will present data in two posters and host a workshop at the Association for Molecular Pathology (AMP) 2020 Annual Meeting & Expo taking place virtually on Nov. 16-20, 2020.   Details of the presentations are as follows:…

Read More

Immunexpress Identifies and Validates Blood Transcriptomic Signatures for Discrimination of Viral and Bacterial Infections in the Emergency Department

Immunexpress.com

Publication in BMC Medicine demonstrates the combination of SeptiCyte® TRIAGE and SeptiCyte® VIRUS can discriminate between bacterial and viral infections in Emergency Department patients SEATTLE, Sept. 23, 2020 /PRNewswire/ — Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, announced today new data in collaboration with researchers at the University College of London. …

Read More

Immunexpress Presents Data on Clinical Validation of SeptiCyte® RAPID for Diagnosing Sepsis at e-ISICEM

Immunexpress.com

Immunexpress, Inc., a medical diagnostic company focused on improving outcomes for suspected sepsis patients, today announced the presentation of analytical and clinical performance data for SeptiCyte® technology in two posters at the virtual e-ISICEM (International Symposium on Intensive Care and Emergency Medicine), from Sept. 15-18, 2020. The first poster, titled “Clinical Performance of a Rapid Sepsis…

Read More

Immunexpress Awarded BARDA Contract to Develop SeptiCyte® RAPID for COVID-19 Patient Triage

Immunexpress.com

Immunexpress, Inc., a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, has been awarded a grant from the Biomedical Advanced Research and Development Authority (“BARDA”), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS), of up to $599,549 to…

Read More